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Response-guided therapy is of limited use in developing countries because hepatitis C virus
RNA  detection by sensitive molecular methods is time- and labor-consuming and expen-
sive.  We  evaluated early predictive efﬁcacy of serum hepatitis C virus core antigen kinetics
on  sustained virologic response in patients with genotype 1 hepatitis C virus during pegy-
lated interferon plus ribavirin treatment. For 478 patients recruited, hepatitis C virus RNAs
were detected at baseline, and at weeks 4, 12, 24, 48, and 72 using Cobas TaqMan. Architect
hepatitis C virus core antigen was performed at baseline, and weeks 4 and 12. Predictive
values of hepatitis C virus core antigen on sustained virologic response were compared to
hepatitis C virus RNA. In the ﬁrst 12 weeks after treatment initiation the dynamic patterns
of  serum hepatitis C virus core antigen and hepatitis C virus RNA levels were similar in sus-
tained virologic response, relapse, and null response patients groups. Although areas under
the  receiver operating characteristics curves of hepatitis C virus core antigen were lower
than those of hepatitis C virus RNA at the same time points, modeling analysis showed thatundetectable hepatitis C virus core antigen (rapid virological response based on hepatitis C
virus  core antigen) had similar positive predictive value on sustained virologic response to
hepatitis C virus RNA at week 4 (90.4% vs 93.3%), and hepatitis C virus core antigen decrease
greater than 1 log10 IU/mL (early virological response based on hepatitis C virus core antigen)
had  similar negative predictive value to hepatitis C virus RNA at week 12 (94.1% vs 95.2%).
Abbreviations: HCV, hepatitis C virus; PegIFN, pegylated interferon; RBV, ribavirin; DAA, direct acting antiviral; CHC, chronic hepatitis
;  SVR, sustained virologic response; LLOD, lower limit of detection; HCVcAg, HCV core antigen; YPegIFN, type Y pegylated interferon
-2b;  RVR, rapid virological response; EVR, early virological response; NR, null response; AUROC, areas under the receiver operating
haracteristics curve; dHCVcAg, decline of HCV core antigen; dHCVRNA, decline of HCV RNA; PPV, positive predictive value; NPV, negative
redictive value; RVR-Ag, RVR based on HCV core antigen; EVR-Ag, EVR based on HCV core antigen.
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Analysis on the validation group demonstrated a positive predictivevalue of 97.5% in rapid
virological response based on hepatitis C virus core antigen and a negative predictive value
of  100% in early virological response based on hepatitis C virus core antigen. In conclusion,
hepatitis C virus core antigen is comparable to hepatitis C virus RNA in predicting sustained
virologic response of chronic genotype 1 hepatitis C virus infected patients, and can be used
to  guide anti-hepatitis C virus treatment, especially in resource-limited areas.
© 2015 Elsevier Editora Ltda. All rights reserved.
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t is estimated that more  than 185 million people around the
orld have been infected with hepatitis C virus (HCV), and
he South Asian and East Asian regions have by far the largest
umber of persons living with HCV infection, where more
han 100 million people were infected by HCV.1 The burden
f disease including the costs of treatment and monitoring
re greater in developing countries.2
Pegylated interferon (PegIFN) plus ribavirin (RBV) was the
tandard of care for patients with chronic HCV infection
efore 2011.3 Following the appearance of direct acting antivi-
al (DAA) drugs when two protease inhibitors (telaprevir and
oceprevir) were licensed for use as the ﬁrst-generation DAAs,
he ﬁeld of anti-HCV treatment is evolving rapidly in chronic
epatitis C (CHC).4 However, the available data for the DAAs
re from drug registration trials, and data on safety and
ong-term effectiveness are also limited because of the small
umber of persons included in the studies in addition to
hort follow-up. Most importantly, DAAs are very expensive;
 12-week course of sofosbuvir costs as much as US$ 84,000
n the US.5 Therefore, it is likely that PegIFN and RBV will
e the only available regimen for the next several years in
ost countries. The WHO  strongly recommends that PegIFN
n combination with RBV be used for the treatment of chronic
CV infection, especially in resource-limited settings.5 Even
he 2014 EASL Guidelines recommend PegIFN/RBV for selected
atients with high likelihood of sustained virologic response
SVR).6
Even standard-of-care regimens have problems related to
igh cost of treatment, requirement for sophisticated labora-
ory testing before and during treatment, high rate of adverse
vents, and unsatisfactory virological response.6,7 It is very
mportant to predict the virologic response in order to adjust
he treatment protocol earlier. Response-guided therapy, in
hich HCV RNA quantiﬁcation should be performed by a
ensitive assay (lower limit of detection (LLOD) <50 IU/mL,
r even <15 IU/mL), is widely used to guide the PegIFN/RBV
ual therapy.6 However, in many  low- and middle-income
ountries, sensitive HCV RNA assays are either not available
r available only in some large cities.5 A simple and inexpen-
ive surrogate marker is therefore required in clinical practice.
t has been reported that HCV core antigen (HCVcAg) reﬂects
iral replication, and its serum level varies following antiviral
reatment in hepatitis C patients.8–10 Early kinetics of serum
CVcAg predicts SVR well in CHC patients on standard-of-care
herapy, and HCVcAg level at week 1 is a stronger predictor
f SVR.11,12 However, both studies had small sample sizes.
hus, further and larger studies were warranted in order toconﬁrm the clinical signiﬁcance of HCVcAg reduction during
treatment.
Accordingly, based on phases IIb and III clinical trials that
examined the safety and efﬁcacy of type Y pegylated inter-
feron -2b (YPegIFN, Pegabin®, Tebao Pharmaceuticals Inc.,
China) in patients with CHC, we performed a comparative
analysis of the early dynamics of HCVcAg and HCV  RNA levels,
and aimed to evaluate the early predictive efﬁcacy of HCVcAg
kinetics on SVR.
Patients  and  methods
Patients
All patients were derived from phases IIb and III clini-
cal trials of YPegIFN, which were multicenter, randomized,
open-labeled, and positive drug-controlled (NCT01140997 and
NCT01581398). According to the trials protocols all patients
were aged 18 through 65 years, had positive anti-HCV and
HCV RNA levels greater than 2000 IU/mL at the last six months,
and evidence of written informed consent. Exclusion criteria
included signiﬁcantly abnormal liver function, pregnancy or
inability to practice adequate contraception, signiﬁcant sys-
temic or major illnesses other than liver disease, preexisting
lower blood cells known history of antiviral or immunosup-
pressive therapy, and evidence of other viral infection.11 In
addition, the current study included only patients infected
with genotype 1 HCV and treated with 180 g PegIFN, and
completed the planned treatment period.
A total of 211 and 816 patients were enrolled and ran-
domized in the phases IIb and III clinical trials, respectively.
In phase IIb trial, 157 patients were excluded due to use
of other PegIFN, non-genotype 1 HCV infection, and loss-
to-follow-up. In phase III trial, 392 patients were excluded
due to non-genotype 1 HCV infection, no treatment initiation
after randomization, loss-to-follow-up, and unavailability of
HCVcAg data. At last, the cohort comprising 478 patients was
analyzed in the present study (Fig. 1).
The study was approved by the ethical committees of
Peking University People’s Hospital and conducted according
to the guidelines of the International Conference on Har-
monization for Good Clinical Practices. The study protocol
conformed to the ethical guidelines of the 1975 Helsinki Dec-
laration.
HCV  testsThe molecular HCV RNA assay is a conﬁrmatory test for
HCV infection using a reverse transcription-polymerase chain
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Phase IIIPhase II b
Genotypes 2
or 3 (n=33)
Patients enrolled and
randomized (n=211)
Patients enrolled and
randomized (n=816)
Genotypes 2
or 3 (n=255)
No treatment
(n=42)
Lost of follow up or
withdrawal (n=49)
Genotype 6
(n=46)
Recruitment (n=424)Recruitment (n=54)
Patients included in the current study (n=478)
Non-genotypes 2
or 3 (n=561)
Lost to follow up or
withdrawal (n=16)
Patients with Non-
genotypes 2 or 3 in
180 μg groups
(n=70)
180 μg groups
(n=103)
180 μg groups
(n=519)
Excluded (n=108)
  No treatment (n=2)
  90 μg YPegIFN (n=54)
  135 μg YPegIFN (n=52)
Fig. 1 – Flowchart of patients enrolled in the current study.reaction (PCR). HCVcAg is detected in a two-step chemi-
luminescent microparticle immunoassay technology.13 The
COBAS AmpliPrep/COBAS TaqMan automated real-time PCR
platform (Roche Molecular Systems, Pleasanton, CA) was used
to quantify HCV RNA levels. This assay has a LLOD of 15 IU/mL
and a lower limit of quantiﬁcation of 43 IU/mL. The Archi-
tect HCVcAg (Abbott Diagnostics, Wiesbaden, Germany) was
used to quantify HCVcAg. As the manufacturer instructed,
HCVcAg levels lower than 3.0 fmol/L were considered non-
reactive. HCV genotyping was based on hybridization of the
ampliﬁed segment of the 5′ non-translated region of the HCV
genome, and performed according to manufacturer’s instruc-
tions (Abbott Diagnostic assay).
IFN  therapy  and  deﬁnitions  of  response  to  IFN  therapy
All patients were treated with YPegIFN or PegIFN-2a (PegIFN)
(180 g, once a week) in combination with RBV (<75 kg, 1000 mg
daily and ≥75 kg, 1200 mg  daily). The duration of treatment
was 48 weeks for genotype 1 HCV infected patients and then
followed up for 24 weeks.
SVR was deﬁned as undetectable HCV RNA level (<15 IU/mL)
at week 24 after cessation of treatment, and rapid virologic
response (RVR) was as undetectable HCV RNA at week 4 of
therapy. Early virologic response (EVR) was deﬁned as more
than 2 log10 IU/mL decrease from baseline level after 12 weeks
of therapy. Null response (NR) was considered when therewas less than 2 log10 IU/mL decrease in HCV  RNA level from
baseline at week 12 of therapy. Reappearance of HCV RNA in
serum after the end of therapy characterized relapse.14 N-SVR
included null response and relapse. DHCVcAg and dHCVRNA
were deﬁned as a log10 reduction of serum HCVcAg and HCV
RNA levels between other time points and baseline, respec-
tively.
Statistical  analysis
Quantitative variables were expressed as mean ± standard
deviation or median (minimum, maximum), and categorical
variables as absolute and relative frequencies. The cate-
gorical variables were compared between groups by the
2 test or Fisher’s exact test, and non-categorical vari-
ables were compared by Student’s t-test, one-way ANOVA or
the Mann–Whitney U-test. The optimal predictive values of
HCVcAg and HCV RNA at different time points were assessed
by calculating the area under the receiver operating character-
istic (AUROC) curves. Sensitivity, speciﬁcity, positive predictive
value (PPV), and negative predictive value (NPV) were calcu-
lated to determine the reliability of predictors of the response
to therapy. All statistical analyses were performed with SPSS
16.0 (Chicago, IL, USA). Two-tailed p-values less than 0.05 were
considered statistically signiﬁcant.
All authors had access to the study data, and reviewed and
approved the ﬁnal manuscript.
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Table 1 – Baseline data for patients with sustained virological response (SVR) and non-sustained virological response
(N-SVR).
SVR N-SVR Statistics p-Value
Male/female (n) 184/194 52/48 2 = 0.349 0.555
Age, mean ± SD (years) 41.52 ± 12.00 46.45 ± 12.34 t = −3.631 <0.001
HCVcAg, median and range (log10 fmol/L) 3.66 (0.55, 4.30) 3.78 (0.48, 4.30) Z = −2.228 0.026
HCV RNA, median and range (log10 IU/mL) 6.23 (3.58, 7.31) 6.33 (3.34, 7.39) Z = −2.379 0.017
YPegIFN/PegIFN-2a (n) 241/137 63/37 2 = 0.020 0.889
SVR, sustained virological response; N-SVR, non-sustained virological response; HCVcAg, hepatitis C virus core antigen; PegIFN, pegylated
interferon; YPegIFN, type Y pegylated interferon -2b.
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results
 total of 478 patients were enrolled in the current study,
f whom 475 (99.4%) patients were infected with genotype
b HCV. There were 236 male and 242 female patients.
he mean age was 41.52 ± 12.23 years old. Mean baseline
iral load and HCVcAg level were 6.00 ± 0.79 log10 IU/mL and
.42 ± 0.74 log10 fmol/L, respectively. Baseline characteristics
ccording to treatment outcome (SVR and N-SVR groups) are
hown in Table 1. SVR patients had older age, higher baseline
CVcAg, and higher HCV RNA than N-SVR patients.
VR  rates  among  patients  treated  with  YPegIFN  and
egIFN˛-2a
f all participants in the current study, 304 and 174 were
reated by 180 g YPegIFN plus RBV and PegIFN-2a plus
BV, respectively. SVR was obtained in 79.3% of patients on
PegIFN, and in 78.7% in patients on PegIFN-2a. Relapse
ccurred in 16.1% and 17.2% of patients receiving YPegIFN
5.00 SVR Rela
4.00
3.00
2.00
1.00
0.00
7.00
6.00
5.00
4.00
3.00
2.00
1.00
0.00
0 4
ig. 2 – Dynamic changes of serum HCVcAg (upper) and HCV RN
rst 12 weeks after initiation of antiviral treatment, serum HCVc
elapse and null response groups.and PegIFN-2a treatment, respectively (2 = 0.174, p = 0.917,
Supplementary ﬁgure).
Supplementary ﬁgure related to this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.bjid.2015.04.007.
Early  kinetics  of  HCVcAg  and  HCV  RNA  levels  with
different  outcomes
In the ﬁrst 12 weeks after initiation of antiviral therapy, kinet-
ics of serum HCVcAg and HCV RNA were similar in SVR,
relapsed and NR patients (Fig. 2). Baseline HCVcAg levels in
SVR, relapsed, and NR patients were not signiﬁcantly differ-
ent, with median values of 3.66, 3.76 and 3.93 log10 fmol/L,
respectively (2 = 2.933, p = 0.231). The same was observed for
baseline median HCV RNA (6.23, 6.28 and 6.51, 2 = 1.953,
p = 0.377). Among the three groups of treatment response, the
most rapid declines in serum HCVcAg and HCV RNA were
observed in SVR patients, whereas NR patients showed the
slowest decline.
pse NR
12
A (lower) levels in patients with different outcomes. In the
Ag and HCV RNA levels presented similar kinetics in SVR,
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Fig. 3 – ROCs of values of HCVcAg and HCV RNA at weeks 4 and 12 to predict SVR. AUROCs were calculated to compare the
values of HCVcAg and HCV RNA at weeks 4 and 12 to predict SVR and identify the best cutoff values. The random classiﬁer
line indicates a 50% post-test probability and the cutoff point represents the best compromise between sensitivity and
speciﬁcity for the two assays.
Accuracy  of  HCVcAg  and  HCV  RNA  declines  at  weeks  4
and 12  of  treatment  to  predict  SVR
ROC curves were used to determine the optimal cutoff val-
ues of HCVcAg and HCV RNA at weeks 4 and 12 that would
maximize prediction of SVR (Fig. 3). Sensitivity, speciﬁcity,
PPV and NPV were calculated using the optimal cutoff values
(Table 2). Likewise, AUROCs of dHCVcAg, dHCVRNA, HCVcAg
and HCV RNA were 0.695, 0.788, 0.775 and 0.803 at week 4, and
0.685, 0.688, 0.638 and 0.739 at week 12, respectively. As for
dHCVcAg and HCVcAg, the highest AUROC for HCVcAg levels
was obtained at week 4. At this time point the AUROC, based
on 0.62 HCVcAg cutoff, was 0.775; the corresponding sensi-
tivity, speciﬁcity, PPV and NPV were, 83.9%, 64.0%, 89.8%, and
51.2%, respectively. At week 4, HCVcAg and HCV RNA declines
had similar PPVs (89.8% and 89.6%).
Accuracy  of  RVR-Ag  and  EVR-Ag  to  predict  SVR
All 424 patients from the phase III trial were regarded as the
model group. RVR-Ag had higher accuracy to predict SVR, with
a PPV similar to RVR of HCV RNA (90.4% and 93.3%), and NPV
of EVR-Ag was similar to EVR of HCV RNA (94.1% and 95.2%)
(Fig. 4). Analysis on the validation group (54 patients from the
phase IIb trial) demonstrated a PPV of 97.5% for RVR-Ag and a
NPV of 100% for EVR-Ag.Clinical  signiﬁcance  of  negative  HCVcAg  at  weeks  4  and
12
At week 4 time point, 333 (69.7%) out of 478 patients with
negative HCVcAg (<3 fmol/L), 137 out of 156 (87.8%) patients
with <3 fmol/L but detectable HCVcAg, and 163 out of 177
(92.1%) patients with undetectable HCVcAg achieved SVR. On
the other hand, 448 out of 478 (93.7%) patients with negative
HCVcAg (<3 fmol/L) at week 12 time point, 14 out of 20 (70.0%)
patients with <3 fmol/L but detectable HCVcAg, and 361 out of
428 (84.3%) patients with undetectable HCVcAg achieved SVR.
Although SVR rate was higher in patients with undetectable
HCVcAg than in patients with negative but detectable HCVcAg,
there was no difference between the two groups at either week
4 or week 12 (week 4: 2 = 1.280, p = 0.258; week 12: 2 = 2.883,
p = 0.090).
Discussion
The test for quantifying HCVcAg was developed in 1999 and
has ever since been increasingly considered to reﬂect replica-
15,16tion of HCV in different circumstances. However, despite
being considered an alternative to HCV RNA assays, HCVcAg
has not been recommended in clinical practice guidelines for
diagnosis and guiding hepatitis C therapy.6,14 Its signiﬁcance
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Table 2 – Area under the ROC curve, sensitivity, speciﬁcity, and predictive values of sustained virological response based on total HCV core antigen and HCV RNA levels
at weeks 4 and 12 after initial antiviral therapy.a
dHCVcAg4 dHCVRNA4 HCVcAg4 HCVRNA4 dHCVcAg12 dHCVRNA12 HCVcAg12 HCVRNA12
AUROC (95% CI) 0.695 (0.632–0.758) 0.788 (0.737–0.840) 0.775 (0.718–0.832) 0.803 (0.755–0.852) 0.685 (0.618–0.752) 0.688 (0.612 –0.755) 0.638 (0.570 –0.707) 0.739 (0.675–0.804)
Cutoff 2.985 3.495 0.620 3.020 1.745 3.535 0.240 4.225
Sensitivity 0.593 0.809 0.839 0.831 0.958 0.984 0.955 1.000
Speciﬁcity 0.700 0.650 0.640 0.630 0.250 0.350 0.310 0.230
PPV 0.882 0.896 0.898 0.895 0.828 0.851 0.840 0.831
NPV 0.313 0.474 0.512 0.630 0.710 0.854 0.646 1.000
HCVcAg, hepatitis C virus core antigen; AUROC, area under the univariate receiver operating characteristic curve; CI, conﬁdence interval; PPV, positive predictive value; NPV, negative predictive value
a All data were presented as log10, and dHCVcAg and dHCVRNA were deﬁned as a log10 reduction of serum HCVcAg and HCV RNA levels between other time points and baseline, respectively.
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Baseline
A
B
Week 4
SVR 93.3%
(n=180)
SVR 66.2%
(n=153)
RVR
(n=193)
EVR
(n=403)
NR (n=21)
dHCVcAg ≥1
 (n=407)
dHCVcAg <1
 (n=17) SVR 5.9%
 (n=1)
SVR 81.6%
 (n=332)
SVR 4.8%
 (n=1)
SVR 82.4%
 (n=332)
PPV 93.3% PPV 82.4%
NPV 33.8%
PPV 90.4% PPV 81.6%
NPV 95.2%
NPV 48.1% NPV 94.1%
non-RVR
(n=231)
SVR 90.4%
(n=265)
SVR 51.9%
(n=68)
non-RVR-Ag
(n=131)
RVR-Ag
(n=293)
All patients
(n=424)
All patients
(n=424)
Week 12
Fig. 4 – Predictive efﬁcacy of RVR and EVR of HCVcAg and HCV RNA at weeks 4 and 12. Analysis on the model group from
the phase III clinical trial showed that undetectable HCVcAg at week 4 (RVR-Ag) had a high positive predictive value of SVR,
and HCVcAg of more  than 1 log10 IU/mL decrease at week 12 (EVR-Ag) had a high negative predictive value.was unclear in clinical practice since it had not been tested in
large clinical trials.
Based on phases IIb and III clinical trials on YPegIFN, 478
patients with genotype 1 HCV infection who completed the
planned treatment duration were analyzed in the current
study. All participants were treated with either 180 g YPegIFN
or 180 g PegIFN-2a both in combination with RBV. There
were no signiﬁcant differences in antiviral outcomes between
YPegIFN and PegIFN-2a groups. Therefore, we pooled the
patients from both groups into one cohort. On the other hand,
older age, higher baseline HCVcAg and HCV RNA levels were
associated with SVR, which could not inﬂuence the compara-
tive analysis of the accuracy of HCVcAg and HCV RNA kinetics
to predict SVR.
At weeks 4 and 12 after initiation of antiviral therapy, sim-
ilar kinetics patterns were observed for both serum HCVcAg
and HCV RNA levels in CHC patients who had SVR, relapse
or NR. Serum HCVcAg and HCV RNA declined most rapidly
in the SVR group, and most slowly in the NR group suggest-
ing that HCVcAg determination may be an alternative way
to predict anti-HCV treatment outcomes. By calculating the
AUROCs, we  assessed the optimal SVR predictive cutoffs of
HCVcAg and dHCVcAg, HCV RNA and dHCV RNA at weeks 4
and 12. We  found that AUROCs of HCVcAg and dHCVcAg were
smaller than those of HCVRNA and dHCVRNA at the same time
points. As for HCVcAg, the biggest AUROC of 0.775 was seen for
HCVcAg levels (not decline of HCVcAg) at week 4 for the 0.62
cutoff value. Such cutoff value yields PPV and NPV of 89.8%
and 51.2%, respectively. At this time point, the PPV of HCVcAgwas similar to that of HCV RNA decline (89.8% and 89.6%). On
the other hand, RVR-Ag, which was deﬁned as undetectable
HCVcAg at week 4 of therapy, had higher accuracy for predict-
ing SVR with a PPV of 90.4%. EVR-Ag, deﬁned as more  than
1 log10 IU/mL decline from baseline, had a PPV of 81.6% and
a NPV of 94.1%. As for those patients with negative HCVcAg,
undetectable HCVcAg was not signiﬁcantly more  predictive of
SVR than negative but detectable HCVcAg.
In our previous study, we detected HCVcAg at 24, 48, 72, 96,
120 and 144 h, and weeks 4, 8 and 12.11 We  found that the high-
est AUROC and the best predictive time point was 144 h after
initiation of antiviral treatment, and the AUROCs decreased
gradually at weeks 4, 8 and 12. Combining with the results of
the present study in which the predictive accuracy of HCVcAg
was comparable to that of HCV RNA at weeks 4 and 12 (that is
RVR and EVR), we think that there are likely better predictive
power and an earlier predictive time point for HCVcAg than
for HCV RNA, but it needs further investigation. Alternatively,
sensitive HCV RNA quantitative assays which meet guidelines
for hepatitis C management, for example COBAS TaqMan HCV
test and Abbott RealTime, are rare in developing countries
including China, and due to its high cost and technical difﬁcul-
ties, HCV RNA testing is batched once or twice a week in many
laboratories.17 Alternatively, we found that the predictive
power of HCVcAg was superior to that of HCV RNA with LLOD
of 500 IU/mL which has been widely used in many  areas of
China because of its lower cost (data not shown). Furthermore,
quantiﬁcation of HCVcAg has some potential advantages as
shown below. It can be performed with a simple operation and
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ess time consuming (within 60 min),18 does not require expert
aboratory staff, and is less expensive than HCV RNA testing
ue to lower costs of equipment and reagents.15,18,19 HCVcAg
s more  stable and its detection is more  reproducible than
CV RNA in clinical samples,9,20,21 and when performed in a
ully automated chemiluminescent microparticle immunoas-
ay has a very low intra- and inter-assay variability.22
Since 2011, triple therapies including the HCV NS3 protease
nhibitors combined with PegIFN and RBV, in which response-
uided therapy based on HCV RNA detection is applied, has
een approved for those patients with chronic HCV geno-
ype 1 infection.3,23 Moreover, IFN-free anti-HCV strategies are
ngoing with promising results.24 Dual therapies of DAAs, like
aclatasvir plus sofosbuvir, have been very successful with
8% SVR12 genotype 1 infected patients.25 In the era of DAAs,
he clinical signiﬁcance of HCVcAg needs to be investigated
nd its accuracy to predict treatment response will probably
e adjusted.
In conclusion, serum HCVcAg could have the same early
inetics patterns as HCV RNA during treatment with PegIFN
nd ribavirin in CHC patients with SVR, relapse or NR.
lthough the sensitivity of HCVcAg testing was lower than
hat of HCV RNA, and AUROCs of HCVcAg and dHCVcAg were
ower than those of HCV RNA and dHCV RNA, RVR and EVR of
CVcAg were comparable to those of HCV RNA, which means
hat HCVcAg may be as meaningful as HCV RNA in reﬂecting
ynamic changes of viral replication and in predicting SVR
arlier during double treatment. As a reliable, faster, more
ost-effective, and less labor-intensive alternative to HCV RNA
esting, HCVcAg could be a promising assay in guiding antivi-
al treatment, especially in low- and middle-income countries.
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